EBiSC2 A sustainable European Bank for induced pluripotent Stem Cells
EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EBISC
European Bank for induced pluripotent Stem Cells
34M€
Cerrado
EASY-IPS
a rapid and efficient method for generation of iPSC
150K€
Cerrado
EBISC
European Bank for induced pluripotent Stem Cells
34M€
Cerrado
CELLNAIVETY
Deciphering the Molecular Foundations and Functional Compete...
2M€
Cerrado
BFU2009-13513
DERIVACION DE LINEAS CELULARES RECOMBINANTES HUMANAS ES/IPS...
424K€
Cerrado
RYC-2009-05080
Reprogramación de telómeros en células madre pluripotenciale...
192K€
Cerrado
Información proyecto EBiSC2
Duración del proyecto: 48 meses
Fecha Inicio: 2019-02-28
Fecha Fin: 2023-02-28
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells (iPSC). Significant progress towards this aim has been made by EBiSC1; further resources, however, are required to ensure self-sustainability. Key partners of EBiSC1 who have delivered major assets of the current bank, join efforts to establish EBiSC2 as self-sustainable, central bank.
Based on a gap analysis of the EBiSC1 endeavours towards sustainability, and focussing on user demand, scientific excellence and productivity, EBiSC2 will deploy a business strategy for a sustainable, non-for-profit bank providing access to disease-relevant and quality-controlled iPSCs, along with comprehensive data and freedom to operate for academic and commercial use. To meet evolving requirements from industry and academia, the cell catalogue will be constantly enriched through on-demand generation of new iPSC lines, including gene-edited lines and isogenic controls, iPSC-derived and progenitor cells. EBiSC2 will distribute cell lines and develop a range of additional cell services (incl. screening panels of disease-relevant iPSC and control lines in ready-to-use-formats) to extend its offer, while reducing operational costs through state-of-the-art upscaling and automation enabling bulk production of standardised high-quality cells. Proof-of-concept studies performed jointly by academia and industry will demonstrate the reliability and robustness of the lines for disease modelling and screening and enrich the EBiSC2 catalogue with extensive data.
To bundle resources, EBiSC2 focuses on collaboration with iPSC programmes and aims to serve as central hub for EU-funded projects to bank their iPSC lines, and thus, enable long-term access by the research community to the results of European investments.